

March 29, 2025

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal
Street Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Ref: Letter(s)/emails received from stock exchanges as Cautionary under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Dear Sir/Madam,

This is in reference to the Corporate Announcements being submitted by Orchid Pharma Limited ("the Company") on June 04, 2024 and June 14, 2024, on which BSE Limited and National Stock Exchange of India Limited ("Stock Exchanges") have issued Caution letters/emails to the Company for acting vigilantly in making timely disclosures to the stock Exchanges to ensure due compliance with the applicable SEBI Listing Regulations and related SEBI circulars.

Further, the details required in terms of Schedule III – Sub-Para 20 of Para A of Part A of the SEBI Listing Regulations, as amended read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 issued in this regard, are given in the annexure enclosed herewith as **Annexure-I**.

Furthermore, copy of the Caution Letter(s)/emails are enclosed herewith as **Annexure-II**.

You are requested to take the above information on record.

Thanking You,

For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer
M. No: F10698

Encl: As above

Annexure- I

Details as per Schedule III – Sub-Para 20 of Para A of Part A of SEBI Listing Regulations read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Details
1.	Name of the authority	BSE Limited & National Stock Exchange of India Limited
2.	Nature and details of the action(s) taken or order(s) passed	The Stock Exchanges have issued Caution Letter(s)/emails.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	28.03.2025
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	Delayed intimations, being less than two working days (excluding the date of intimation and due date of the meet), by Company for Schedule of Investors/Analysts' Meet/Call scheduled on June 05 & 06, 2024 and June 18 & 19, 2024 via announcements dated June 04, 2024 and June 14, 2024 respectively.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	We believe that the Caution Letter(s)/emails have no material impact on the financial, operation or other activities of the Company.

From: Query lodr <query.lodr@bseindia.com>
Sent: 28 March 2025 16:26
To: Company Secretary (Secretarial)
Subject: Cautionary Letter

You don't often get email from query.lodr@bseindia.com. [Learn why this is important](#)

LIST/COMP/JP/1746/2024-25
March 28, 2025

Date:

To,
Company Secretary /Compliance Officer
Orchid Pharma Ltd (524372)

Sub: Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 04, 2024, regarding the intimation of Schedule of Investors/ Analysts' Meet/ Call to be held on June 05 & 06, 2024

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet/call).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team

BSE Limited

P J Towers, Dalal Street,
Mumbai - 400001, India

www.bseindia.com

Tel: 022 2272 8561 / 8475

This mail is classified as 'CONFIDENTIAL' by chetan.ag on March 28, 2025 at 16:26:27.

DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects.

DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects.

From: Query lodr <query.lodr@bseindia.com>
Sent: 28 March 2025 16:30
To: Company Secretary (Secretarial)
Subject: Cautionary Letter

You don't often get email from query.lodr@bseindia.com. [Learn why this is important](#)

LIST/COMP/JP/1788/2024-25
March 28, 2025

Date:

To,
Company Secretary /Compliance Officer
Orchid Pharma Ltd (524372)

Sub: Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 14, 2024, regarding the intimation of Schedule of Investors/ Analysts' Meet/ Call to be held on June 18 and 19, 2024

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet/call).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team

BSE Limited

P J Towers, Dalal Street,
Mumbai - 400001, India

www.bseindia.com

Tel: 022 2272 8561 / 8475

This mail is classified as 'CONFIDENTIAL' by chetan.ag on March 28, 2025 at 16:29:56.

DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects.

DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects.

From: neaps@nse.co.in
Sent: 28 March 2025 18:01
To: Company Secretary (Secretarial)
Subject: ORCHPHARMA - Cautionary Email

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 04, 2024 regarding the intimation of Schedule of Investors/ Analysts Meet/call to be held on June 05 and 06, 2024.

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.

Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.

Preeti Yadav

From: neaps@nse.co.in
Sent: 28 March 2025 18:11
To: Company Secretary (Secretarial)
Subject: ORCHPHARMA - Cautionary Email

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 14, 2024 regarding the intimation of Schedule of Investors/ Analysts Meet/call to be held on June 18 and 19, 2024.

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.

Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.